HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Robitussin Gets Natural With Honey, Ivy Leaf, Eucalyptus Supplements For Cough Relief

Executive Summary

GSK launches Robitussin Naturals drug-free cough and cold remedies in the first naturals offering under the top-selling OTC drug brand. The line includes liquids and gummies for adults and children formulated with honey, ivy leaf and eucalyptus.

You may also be interested in...



GSK Consumer Split Set For July, With Emerging Markets And Switch To Drive Growth

GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.

Mucinex Children’s FreeFrom; PURA CBD For Pets, Sweets and Lovers; Health & Wellness Product News

Reckitt Benckiser extends its Mucinex FreeFrom cold and flu line into children’s products, offering OTC active ingredients but without additives, artificial colors, flavors and sugar. Applied Biological Laboratories touts research suggesting its new Biovanta throat lozenges and sprays with aspirin and natural ingredients such as honey can help control upper respiratory inflammation. News in brief.

J&J Producing Tylenol ‘24-7’ As US OTC Sales Jump 35% On Pandemic-Driven Stockpiling

J&J is prioritizing Tylenol production on caplets easiest to manufacture to maximize output as it manufactures the line around the clock, says CEO Alex Gorsky. First-quarter US OTC sales soared 35% as consumers stockpiled due to COVID-19, though the pandemic led J&J to downgrade its 2020 outlook.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150717

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel